Skip Navigation

COVID-19 Update

We continue to monitor COVID-19 cases in our area and providers will notify you if there are scheduling changes. Please continue to call your providers with health concerns. We are providing in-person care and telemedicine appointments.

Learn about our expanded patient care options and visitor guidelines.

General Information | Self-Checker | Donate and Lend Support | Staff Appreciation | Get Email Alerts

Find a Doctor

Find a Researcher


Michael Jon Pishvaian, M.D., Ph.D.

Photo of Dr. Michael Jon Pishvaian, M.D., Ph.D.
  • Associate Professor of Oncology


Dr. Michael Pishvaian is the director of Gastrointestinal, Developmental Therapeutics and Clinical Research Programs for the Johns Hopkins Kimmel Cancer Center in the Greater Washington Area and an associate professor at the School of Medicine. 

Dr. Pishvaian is a fellowship-trained gastrointestinal oncologist specializing in pancreatic and refractory colorectal cancers. He is committed to precision medicine and provides his patients with the most appropriate and advanced level of care. He conducts all phases of clinical trials for all GI cancers and enrolls qualifying patients. 

Click here to learn more about oncology clinical trials the Greater Washington Area. more


  • Associate Professor of Oncology

Departments / Divisions



  • MD, Georgetown University School of Medicine (2001)


  • MedStar Georgetown University Medical Center / Internal Medicine (2004)


  • MedStar Georgetown University Medical Center / Hematology and Oncology (2007)

Research & Publications

Selected Publications

Pishvaian MJ, Bender RJ, Halverson D, Rahib L, Hendifar AE, Mikhail S, Chung V, Picozzi VJ, Sohal D, Blais EM, Mason K, Lyons EE, Matrisian LM, Brody JR, Madhavan S, Petricoin EF. Molecular Profiling of Pancreatic Cancer Patients: Initial Results from the Know Your Tumor Initiative. Clin Cancer Res. 2018 Jun 28. pii: clincanres.0531.2018. doi: 10.1158/1078-0432.CCR-18-0531. [Epub ahead of print] PMID: 29954777

Brar G, Blais EM, Joseph Bender R, Brody JR, Sohal D, Madhavan S, Picozzi VJ, Hendifar AE, Chung VM, Halverson D, Mikhail S, Matrisian LM, Rahib L, Petricoin E, Pishvaian MJ. Multi-omic molecular comparison of primary versus metastatic pancreatic tumours. Br J Cancer. 2019 Jul 11. doi: 10.1038/s41416-019-0507-5. [Epub ahead of print] PMID: 31292535

Pishvaian MJ, Blais EM, Brody JR, Rahib L, Lyons E, De Arbeloa P, Hendifar A, Mikhail S, Chung V, Sohal DPS, Leslie S, Mason K, Tibbets L, Madhavan S, Matrisian LM, Petricoin III E. Outcomes in Patients With Pancreatic Adenocarcinoma With Genetic Mutations in DNA Damage Response Pathways: Results From the Know Your Tumor Program. JCO Precis Oncol. 2019. DOI https://doi. org/10.1200/PO.19. 00115

Pishvaian MJ, Blais EM, Bender RJ, Rao S, Boca SM, Chung V, Hendifar AE, Mikhail S, Sohal DPS, Pohlmann PR, Moore KN, He K, Monk BJ, Coleman RL, Herzog TJ, Halverson DD, DeArbeloa P, Petricoin EF 3rd, Madhavan S. A virtual molecular tumor board to improve efficiency and scalability of delivering precision oncology to physicians and their patients. JAMIA Open. 2019 Oct 7;2(4):505-515. doi: 10.1093/jamiaopen/ooz045. eCollection 2019 Dec. PMID: 32025647

Pishvaian MJ, Blais EM, Brody JR, Lyons E, DeArbeloa P, Hendifar A, Mikhail S, Chung V, Sahai V, Sohal DPS, Bellakbira S, Thach D, Rahib L, Madhavan S, Matrisian LM, Petricoin EF 3rd. Overall Survival in Patients With Pancreatic Cancer Receiving Matched Therapies Following Molecular Profiling: A Retrospective Analysis of the Know Your Tumor Registry Trial. Lancet Oncol. 2020 Mar 2. pii: S1470-2045(20)30074-7. doi: 10.1016/S1470-2045(20)30074-7. [Epub ahead of print] PMID: 32135080

Patient Ratings & Comments

The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

  • ...Loading ratings...
  • ... 
  • ... 
  • ... 
  • ... 
  • ... 


Is this you? Edit Profile
back to top button